Funder
Institute for Medical Biometry, Informatics and Epidemiology (IMBIE) at the University Hospital of Bonn
German Federal Institute for Drugs and Medical Devices
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Toxicology
Reference49 articles.
1. Moore N, Berdaï D, Blin P, Droz C. Pharmacovigilance—the next chapter. Therapies. 2019. https://doi.org/10.1016/j.therap.2019.09.004.
2. Dubrall D, Schmid M, Alešik E, Paeschke N, Stingl J, Sachs B. Frequent adverse drug reactions, and medication groups under suspicion. Deutsches Ärzteblatt Int. 2018. https://doi.org/10.3238/arztebl.2018.0393.
3. Borg J-J, Aislaitner G, Pirozynski M, Mifsud S. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to?: A review of the new EU legislation on pharmacovigilance. Drug Saf. 2011. https://doi.org/10.2165/11586620-000000000-00000.
4. European Medicines Agency and Heads of Medicines Agencies. Guideline on good pharmacovigilance practices (GVP) Module VI: collection, management and submission of reports of suspected adverse reactions to medicinal products [EMA/873138/2011 Rev 2]. 2017. www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2017/08/WC500232767.pdf. Accessed 9 Dec 2022.
5. European Commission. Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010. https://link.springer.com/content/pdf/10.1007/s40264-018-0647-1.pdf?pdf=button. Accessed 9 Dec 2022.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献